Background: XIENCE V USA is a prospective, multicenter, single-arm, FDA condition-of-approval study to evaluate the safety and effectiveness of the XIENCE VÒ Everolimus Eluting Stent (XIENCE V, Abbott Vascular, Santa Clara, CA) in a realworld, all-comer population. Clinical outcomes at 1 year in AMI patients have been previously reported with low rates of target lesion revascularization (TLR), cardiac death, MI and stent thrombosis (ST). Whether these early results from XIENCE V USA in AMI are sustained long term has not been reported.
Conclusions:
In this large, multicenter, real-world study, low clinical event rates at 1 year were sustained through 4 years. Although the rates of clinical outcomes in AMI patients were slightly higher than those in non-AMI patients, the rates remained low in both groups. A stent design that combines thin struts, a durable fluoropolymer and optimal drug dose likely underlies low long term event rates, even in thrombotic lesions.
TCT-40 10 mg/L of high-sensitivity C-reactive protein on admission is a powerful predictive marker in patients with ST-segment elevation myocardial infarction, but not in patients with non-ST-segment elevation myocardial infarction Background: C-reactive protein is an important inflammatory marker even in acute phase. Limited date are available whether high-sensitivity C-reactive protein (hs-CRP) on admission predicts long-term clinical outcome depending on clinical presentation defined as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). Methods: We enrolled consecutive 3,962 acute myocardial infarction (AMI) patients who underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnvergent REgistry of cAtholic and chonnAm university for AMI) from January 2004 to December 2009. The primary endpoint was a composite of all-cause death, any myocardial infarction, and any revascularization. Cut-off level of initial hs-CRP was 10 mg/L. Results: Median follow up duration was 38.3 months (interquartile range 22.8 to 55.9months). Elevated hs-CRP was observed in 1,439 patients (36.3%). The rate of primary endpoint was higher in high hs-CRP group (37.5% vs. 25.8%; 540 events vs. 652 events, P< 0.001). In multivariable Cox proportional hazards regression, high hs-CRP level is independent predictor of primary endpoint (hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.06-1.36, P¼0.003). In subgroup analysis, higher hs-CRP level is associated with long-term clinical outcome in STEMI, but not in NSTEMI (HR 1.29, 95% CI 1.10-1.52, P¼0.002. vs. HR 1.13, 95% CI 0.94-1.37, P¼0.20; Interaction P¼0.023).
Hs-CRP level on admission over than 10 mg/L is independent predictor for long-term clinical outcome in patients with STEMI, but not in patients with NSTEMI.
TCT-41

CAUSES OF MORTALITY AFTER PERCUTANEOUS CORONARY INTERVENTION IN A LARGE REGIONAL CARDIAC CENTRE IN CANADA
Albert W. Chan 1 , Gerald J. Simkus 1 , Tina Yang 2 , Helen Elliott 1 , Jahangir Charania 1 , Johannes Vuurmans 1 , Roger Philipp 1 1 Royal Columbian Hospital, New Westminster, BC, 2 Cardiac Services of British Columbia, Vancouver, BC Background: Mortality after percutaneous coronary intervention (PCI) is considered as a surrogate marker for the quality of care in interventional cardiology. But mortality after PCI may be related to multiple factors. We examine the frequencies and the causes of mortality after PCI in the contemporary practice. Methods: Royal Columbian Hospital is the tertiary regional cardiac centre of Fraser Health Region in British Columbia that has a population of 1.9 million, and it provides 24/7 primary STEMI revascularization service for the region. Patients' demographics and procedural data are prospectively recorded in the provincial catheterization database, which is linked to the vital statistics. The cause of death was reviewed independently by 2 interventional cardiologists through chart review, and was classified into 3 categories: (1) PCI-related, (2) non-PCI-related cardiac death, and (3) non-cardiac death. Patients who died suddenly or out-of-the-hospital were all presumed to have PCI-related death due to stent thrombosis, unless proven otherwise. Results: From 06/2011 to 12/2013, 6,041 PCI procedures were performed, and 1,847 (31%) cases were done during acute STEMI. A total of 154 (2.5%) patients died 
